In Vitro Effects of Boric Acid on Cell Cycle, Apoptosis, and miRNAs in Medullary Thyroid Cancer Cells

Medullary thyroid cancer (MTC) is a highly aggressive and chemotherapy-resistant cancer originating from the thyroid's parafollicular C cells. Due to its resistance to conventional treatments, alternative therapies such as boric acid have been explored. Boric acid, a boron-based compound, has s...

Full description

Saved in:
Bibliographic Details
Published in:Biological trace element research
Main Authors: Yıldırım, Onurcan, Seçme, Mücahit, Dodurga, Yavuz, Mete, Gülçin Abban, Fenkci, Semin Melahat
Format: Journal Article
Language:English
Published: United States 30-04-2024
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Medullary thyroid cancer (MTC) is a highly aggressive and chemotherapy-resistant cancer originating from the thyroid's parafollicular C cells. Due to its resistance to conventional treatments, alternative therapies such as boric acid have been explored. Boric acid, a boron-based compound, has shown anticarcinogenic effects, positioning it as a potential treatment option for MTC. TT medullary thyroid carcinoma cell line (TT cells) and human thyroid fibroblast (HThF cells) were utilized for the cell culture experiments. Cell viability was assessed using the 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay. Total RNA was extracted using Trizol reagent for gene expression and microRNA (miRNA) analysis via reverse transcription-polymerase chain reaction (RT-PCR). The extent of apoptosis induced by boric acid was determined using the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Colony formation assays were conducted to evaluate the impact of boric acid on the colony-forming ability of MTC cells. At 48 h, 50% inhibitory concentration (IC50) of boric acid was found to be 35 μM. Treatment with boric acid resulted in significant modulation of apoptosis-related genes and miRNAs, including increased expression of phorbol-12-myristate-13-acetate-induced protein 1(NOXA), apoptotic protease activating factor 1 (APAF-1), Bcl-2-associated X protein (Bax), caspase-3, and caspase-9. In contrast, the expression of B cell lymphoma 2 (Bcl2), B cell lymphoma- extra-large (Bcl-xl), and microRNA-21 (miR-21), which are linked to the aggressiveness of MTC, was significantly reduced. The TUNEL assay indicated a 14% apoptosis rate, and there was a 67.9% reduction in colony formation, as shown by the colony formation assay. Our study suggests that boric acid may have anticancer activity in MTC by modulating apoptotic pathways. These findings suggest that boric acid could be a potential therapeutic agent for MTC and possibly for other malignancies with similar pathogenic mechanisms.
AbstractList Medullary thyroid cancer (MTC) is a highly aggressive and chemotherapy-resistant cancer originating from the thyroid’s parafollicular C cells. Due to its resistance to conventional treatments, alternative therapies such as boric acid have been explored. Boric acid, a boron-based compound, has shown anticarcinogenic effects, positioning it as a potential treatment option for MTC. TT medullary thyroid carcinoma cell line (TT cells) and human thyroid fibroblast (HThF cells) were utilized for the cell culture experiments. Cell viability was assessed using the 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay. Total RNA was extracted using Trizol reagent for gene expression and microRNA (miRNA) analysis via reverse transcription-polymerase chain reaction (RT-PCR). The extent of apoptosis induced by boric acid was determined using the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Colony formation assays were conducted to evaluate the impact of boric acid on the colony-forming ability of MTC cells. At 48 h, 50% inhibitory concentration (IC50) of boric acid was found to be 35 μM. Treatment with boric acid resulted in significant modulation of apoptosis-related genes and miRNAs, including increased expression of phorbol-12-myristate-13-acetate-induced protein 1 ( NOXA), apoptotic protease activating factor 1 ( APAF-1 ), Bcl-2-associated X protein ( Bax), caspase-3, and caspase-9 . In contrast, the expression of B cell lymphoma 2 ( Bcl2 ), B cell lymphoma‐ extra-large ( Bcl-xl ), and microRNA-21 (miR-21) , which are linked to the aggressiveness of MTC, was significantly reduced. The TUNEL assay indicated a 14% apoptosis rate, and there was a 67.9% reduction in colony formation, as shown by the colony formation assay. Our study suggests that boric acid may have anticancer activity in MTC by modulating apoptotic pathways. These findings suggest that boric acid could be a potential therapeutic agent for MTC and possibly for other malignancies with similar pathogenic mechanisms.
Medullary thyroid cancer (MTC) is a highly aggressive and chemotherapy-resistant cancer originating from the thyroid's parafollicular C cells. Due to its resistance to conventional treatments, alternative therapies such as boric acid have been explored. Boric acid, a boron-based compound, has shown anticarcinogenic effects, positioning it as a potential treatment option for MTC. TT medullary thyroid carcinoma cell line (TT cells) and human thyroid fibroblast (HThF cells) were utilized for the cell culture experiments. Cell viability was assessed using the 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay. Total RNA was extracted using Trizol reagent for gene expression and microRNA (miRNA) analysis via reverse transcription-polymerase chain reaction (RT-PCR). The extent of apoptosis induced by boric acid was determined using the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Colony formation assays were conducted to evaluate the impact of boric acid on the colony-forming ability of MTC cells. At 48 h, 50% inhibitory concentration (IC50) of boric acid was found to be 35 μM. Treatment with boric acid resulted in significant modulation of apoptosis-related genes and miRNAs, including increased expression of phorbol-12-myristate-13-acetate-induced protein 1(NOXA), apoptotic protease activating factor 1 (APAF-1), Bcl-2-associated X protein (Bax), caspase-3, and caspase-9. In contrast, the expression of B cell lymphoma 2 (Bcl2), B cell lymphoma- extra-large (Bcl-xl), and microRNA-21 (miR-21), which are linked to the aggressiveness of MTC, was significantly reduced. The TUNEL assay indicated a 14% apoptosis rate, and there was a 67.9% reduction in colony formation, as shown by the colony formation assay. Our study suggests that boric acid may have anticancer activity in MTC by modulating apoptotic pathways. These findings suggest that boric acid could be a potential therapeutic agent for MTC and possibly for other malignancies with similar pathogenic mechanisms.
Medullary thyroid cancer (MTC) is a highly aggressive and chemotherapy-resistant cancer originating from the thyroid's parafollicular C cells. Due to its resistance to conventional treatments, alternative therapies such as boric acid have been explored. Boric acid, a boron-based compound, has shown anticarcinogenic effects, positioning it as a potential treatment option for MTC. TT medullary thyroid carcinoma cell line (TT cells) and human thyroid fibroblast (HThF cells) were utilized for the cell culture experiments. Cell viability was assessed using the 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay. Total RNA was extracted using Trizol reagent for gene expression and microRNA (miRNA) analysis via reverse transcription-polymerase chain reaction (RT-PCR). The extent of apoptosis induced by boric acid was determined using the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Colony formation assays were conducted to evaluate the impact of boric acid on the colony-forming ability of MTC cells. At 48 h, 50% inhibitory concentration (IC50) of boric acid was found to be 35 μM. Treatment with boric acid resulted in significant modulation of apoptosis-related genes and miRNAs, including increased expression of phorbol-12-myristate-13-acetate-induced protein 1(NOXA), apoptotic protease activating factor 1 (APAF-1), Bcl-2-associated X protein (Bax), caspase-3, and caspase-9. In contrast, the expression of B cell lymphoma 2 (Bcl2), B cell lymphoma- extra-large (Bcl-xl), and microRNA-21 (miR-21), which are linked to the aggressiveness of MTC, was significantly reduced. The TUNEL assay indicated a 14% apoptosis rate, and there was a 67.9% reduction in colony formation, as shown by the colony formation assay. Our study suggests that boric acid may have anticancer activity in MTC by modulating apoptotic pathways. These findings suggest that boric acid could be a potential therapeutic agent for MTC and possibly for other malignancies with similar pathogenic mechanisms.
Author Seçme, Mücahit
Dodurga, Yavuz
Yıldırım, Onurcan
Mete, Gülçin Abban
Fenkci, Semin Melahat
Author_xml – sequence: 1
  givenname: Onurcan
  orcidid: 0009-0006-2998-4877
  surname: Yıldırım
  fullname: Yıldırım, Onurcan
  email: dronurcanyildirim@gmail.com
  organization: Department of Internal Medicine, Ege University School of Medicine, Izmir, 35100, Turkey. dronurcanyildirim@gmail.com
– sequence: 2
  givenname: Mücahit
  surname: Seçme
  fullname: Seçme, Mücahit
  organization: Department of Medical Biology, Ordu University School of Medicine, Ordu, Turkey
– sequence: 3
  givenname: Yavuz
  surname: Dodurga
  fullname: Dodurga, Yavuz
  organization: Department of Medical Biology, Pamukkale University School of Medicine, Denizli, Turkey
– sequence: 4
  givenname: Gülçin Abban
  surname: Mete
  fullname: Mete, Gülçin Abban
  organization: Department of Histology and Embriology, Pamukkale University School of Medicine, Denizli, Turkey
– sequence: 5
  givenname: Semin Melahat
  surname: Fenkci
  fullname: Fenkci, Semin Melahat
  organization: Department of Endocrinology and Metabolism, Pamukkale University School of Medicine, Denizli, Turkey
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38689139$$D View this record in MEDLINE/PubMed
BookMark eNo9kMlOwzAURS1URAf4ARbISxYNeEocL0NUBqmAhApby_UggpI42Mmif09oC6u3uefqvjMHk9a3FoBLjG4wQvw2YoIwThBhCWI4zxN6AmY4TUWCOEETMEM4owkTOZuCeYxfCGFOBD0DU5pnucBUzIB9auFH1QcPV85Z3UfoHbzzodKw0JWBvoWlrWtY7nRtl7DofNf7WMUlVK2BTfX2UkRYtfDZmqGuVdjBzecu-JEsVatt2NPxHJw6VUd7cbwL8H6_2pSPyfr14aks1okmIu8TnDlndEbTjDjMU020M4ptqbMcc55lirMUMa0tSRW2RmlCUS7MGGQaGb2lC3B96O2C_x5s7GVTRT0uUK31Q5QUMcGx4CIfo-QQ1cHHGKyTXaia8QGJkfzVKw965ahX7vVKOkJXx_5h21jzj_z5pD9gcXZs
Cites_doi 10.1177/20420188211049611
10.3390/ijms23052805
10.1007/s12011-023-03864-0
10.3389/fendo.2021.708949
10.1155/2017/4915736
10.1016/j.canlet.2004.06.001
10.1007/s10534-014-9809-5
10.13201/j.issn.1001-1781.2018.22.018
10.3892/br.2016.747
10.1038/s41574-021-00470-9
10.1007/s12011-007-8081-8
10.1089/thy.2014.0335
10.1038/s41598-020-65207-6
10.1089/thy.2012.0045
10.1016/j.xphs.2020.04.015
10.1074/jbc.M114.619833
10.1016/j.yexmp.2017.10.002
10.1007/s004280000233
10.1007/s12011-019-01739-x
10.1016/j.humpath.2014.09.006
10.1038/cdd.2017.186
10.1371/journal.pone.0059639
10.2174/1568009618666180308105048
10.1002/bab.2233
10.1093/advances/nmz110
10.1016/j.biochi.2017.02.001
10.1016/j.jtemb.2022.126958
10.4238/gmr.15028300
10.1007/s12011-016-0824-y
10.1038/bjc.2014.157
10.3390/cells10040955
10.18632/oncotarget.15098
10.1016/j.jtemb.2022.127043
10.1007/s12011-018-1280-7
10.1016/j.jtemb.2022.126923
10.1039/b823234b
10.1016/j.canep.2014.05.001
ContentType Journal Article
Copyright 2024. The Author(s).
Copyright_xml – notice: 2024. The Author(s).
DBID NPM
AAYXX
CITATION
7X8
DOI 10.1007/s12011-024-04188-3
DatabaseName PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic
PubMed
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 1559-0720
ExternalDocumentID 10_1007_s12011_024_04188_3
38689139
Genre Journal Article
GroupedDBID ---
-4W
-56
-5G
-BR
-EM
-~C
-~X
.86
.VR
06C
06D
0R~
0VY
199
1N0
203
23N
29~
2J2
2JN
2JY
2KG
2KM
2LR
2~H
30V
4.4
406
408
40D
40E
5GY
5VS
67N
6NX
78A
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHBH
AAHNG
AAIAL
AAJBT
AAJKR
AANZL
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYZH
ABAKF
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABJNI
ABJOX
ABKCH
ABMNI
ABMQK
ABNWP
ABOCM
ABPLI
ABQBU
ABSXP
ABTEG
ABTHY
ABTKH
ABTMW
ABWNU
ABXPI
ACAOD
ACCUX
ACDTI
ACGFS
ACGOD
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPRK
ACSNA
ACZOJ
ADBBV
ADHHG
ADHIR
ADINQ
ADKNI
ADKPE
ADNWM
ADTPH
ADURQ
ADYFF
ADZKW
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFLOW
AFQWF
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHMBA
AHSBF
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
AXYYD
B-.
BA0
BBNVY
BENPR
BGNMA
BHPHI
CS3
CSCUP
DDRTE
DNIVK
DPUIP
DU5
EBLON
EBS
EIOEI
ESBYG
F5P
FERAY
FFXSO
FIGPU
FNLPD
FRRFC
FWDCC
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
HCIFZ
HF~
HG6
HMJXF
HRMNR
HZ~
IJ-
IKXTQ
ITM
IWAJR
I~X
I~Z
J-C
J0Z
JBSCW
JZLTJ
KOV
LLZTM
M4Y
M7P
MA-
NB0
NF0
NPM
NPVJJ
NQJWS
NU0
O93
O9G
O9I
O9J
P19
PF0
PT4
PT5
QOK
QOR
QOS
R89
R9I
RHV
RNS
ROL
RPX
RSV
S16
S1Z
S27
S3A
S3B
SAP
SBL
SBY
SDH
SDM
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SZN
T13
TSG
TUC
U2A
U9L
UG4
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W48
WK8
YLTOR
YZZ
Z7U
Z7V
Z7W
Z83
Z87
Z8O
Z8P
Z8Q
Z91
ZMTXR
ZOVNA
~02
~A9
~EX
~KM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c298t-16ffdc63562f175c2cfda4b3fe717766a74504cce25a1edac23089d5c24c0dcb3
ISSN 0163-4984
IngestDate Sat Oct 26 05:32:46 EDT 2024
Fri Nov 22 00:21:13 EST 2024
Sat Nov 02 12:20:55 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords Boric acid
miRNA
TT cells
Medullary thyroid cancer
Cell cycle
Apoptosis
Language English
License 2024. The Author(s).
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c298t-16ffdc63562f175c2cfda4b3fe717766a74504cce25a1edac23089d5c24c0dcb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0009-0006-2998-4877
OpenAccessLink https://link.springer.com/content/pdf/10.1007/s12011-024-04188-3.pdf
PMID 38689139
PQID 3049719798
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3049719798
crossref_primary_10_1007_s12011_024_04188_3
pubmed_primary_38689139
PublicationCentury 2000
PublicationDate 2024-04-30
PublicationDateYYYYMMDD 2024-04-30
PublicationDate_xml – month: 04
  year: 2024
  text: 2024-04-30
  day: 30
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Biological trace element research
PublicationTitleAlternate Biol Trace Elem Res
PublicationYear 2024
References WT Barranco (4188_CR15) 2004; 216
YH Feng (4188_CR33) 2016; 5
D Salvatore (4188_CR5) 2021; 17
C Mian (4188_CR31) 2012; 22
AS Acerbo (4188_CR14) 2009; 134
MA Bartz-Kurycki (4188_CR3) 2021; 12
SA Wells Jr (4188_CR1) 2015; 25
YH Chu (4188_CR30) 2017; 103
4188_CR16
LH Sun (4188_CR32) 2020; 10
E Cavedon (4188_CR34) 2017; 9
E Kahraman (4188_CR19) 2022; 73
A Lopalco (4188_CR37) 2020
F Galuppini (4188_CR7) 2021; 10
E Cebeci (4188_CR12) 2022; 70
J Kale (4188_CR20) 2018; 25
G Pennelli (4188_CR29) 2014; 46
M Sevimli (4188_CR11) 2022; 71
M Asadi (4188_CR17) 2022; 69
SE Kobylewski (4188_CR28) 2017; 176
F Faião-Flores (4188_CR23) 2013; 8
R Scorei (4188_CR13) 2008; 122
H Wang (4188_CR36) 2014; 111
P Li (4188_CR18) 2017; 8
H Khaliq (4188_CR22) 2018; 186
JZ Zhao (4188_CR2) 2018; 32
KA Henderson (4188_CR10) 2015; 28
FH Nielsen (4188_CR8) 2020; 11
4188_CR24
R Bagheri-Yarmand (4188_CR26) 2015; 290
R Shakeri (4188_CR27) 2017; 135
B Smolarz (4188_CR6) 2022; 23
4188_CR9
4188_CR4
R Hinze (4188_CR21) 2000; 437
RZ Morsi (4188_CR25) 2018; 18
L Yu (4188_CR35) 2014; 38
References_xml – volume: 12
  start-page: 204201882110496
  year: 2021
  ident: 4188_CR3
  publication-title: Ther Adv Endocrinol Metab
  doi: 10.1177/20420188211049611
  contributor:
    fullname: MA Bartz-Kurycki
– volume: 23
  start-page: 2805
  issue: 5
  year: 2022
  ident: 4188_CR6
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms23052805
  contributor:
    fullname: B Smolarz
– ident: 4188_CR24
  doi: 10.1007/s12011-023-03864-0
– ident: 4188_CR4
  doi: 10.3389/fendo.2021.708949
– volume: 9
  start-page: 4915736
  year: 2017
  ident: 4188_CR34
  publication-title: Int J Endocrinol
  doi: 10.1155/2017/4915736
  contributor:
    fullname: E Cavedon
– volume: 216
  start-page: 21
  year: 2004
  ident: 4188_CR15
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2004.06.001
  contributor:
    fullname: WT Barranco
– volume: 28
  start-page: 133
  issue: 1
  year: 2015
  ident: 4188_CR10
  publication-title: Biometals
  doi: 10.1007/s10534-014-9809-5
  contributor:
    fullname: KA Henderson
– volume: 32
  start-page: 1754
  issue: 22
  year: 2018
  ident: 4188_CR2
  publication-title: J Clin Otorhinolaryngol Head Neck Surg
  doi: 10.13201/j.issn.1001-1781.2018.22.018
  contributor:
    fullname: JZ Zhao
– volume: 5
  start-page: 395
  year: 2016
  ident: 4188_CR33
  publication-title: Biomed Rep
  doi: 10.3892/br.2016.747
  contributor:
    fullname: YH Feng
– volume: 17
  start-page: 296
  issue: 5
  year: 2021
  ident: 4188_CR5
  publication-title: Nat Rev Endocrinol
  doi: 10.1038/s41574-021-00470-9
  contributor:
    fullname: D Salvatore
– volume: 122
  start-page: 197
  issue: 3
  year: 2008
  ident: 4188_CR13
  publication-title: Biol Trace Elem Res
  doi: 10.1007/s12011-007-8081-8
  contributor:
    fullname: R Scorei
– volume: 25
  start-page: 567
  issue: 6
  year: 2015
  ident: 4188_CR1
  publication-title: Thyroid
  doi: 10.1089/thy.2014.0335
  contributor:
    fullname: SA Wells Jr
– volume: 10
  start-page: 8271
  issue: 1
  year: 2020
  ident: 4188_CR32
  publication-title: Sci Rep
  doi: 10.1038/s41598-020-65207-6
  contributor:
    fullname: LH Sun
– volume: 22
  start-page: 890
  year: 2012
  ident: 4188_CR31
  publication-title: Thyroid
  doi: 10.1089/thy.2012.0045
  contributor:
    fullname: C Mian
– year: 2020
  ident: 4188_CR37
  publication-title: J Pharm Sci
  doi: 10.1016/j.xphs.2020.04.015
  contributor:
    fullname: A Lopalco
– volume: 290
  start-page: 11749
  year: 2015
  ident: 4188_CR26
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M114.619833
  contributor:
    fullname: R Bagheri-Yarmand
– volume: 103
  start-page: 229
  year: 2017
  ident: 4188_CR30
  publication-title: Exp Mol Pathol
  doi: 10.1016/j.yexmp.2017.10.002
  contributor:
    fullname: YH Chu
– volume: 437
  start-page: 256
  year: 2000
  ident: 4188_CR21
  publication-title: Virchows Arch
  doi: 10.1007/s004280000233
  contributor:
    fullname: R Hinze
– ident: 4188_CR9
  doi: 10.1007/s12011-019-01739-x
– volume: 46
  start-page: 50
  year: 2014
  ident: 4188_CR29
  publication-title: Hum Pathol
  doi: 10.1016/j.humpath.2014.09.006
  contributor:
    fullname: G Pennelli
– volume: 25
  start-page: 65
  issue: 1
  year: 2018
  ident: 4188_CR20
  publication-title: Cell Death Differ
  doi: 10.1038/cdd.2017.186
  contributor:
    fullname: J Kale
– volume: 8
  issue: 3
  year: 2013
  ident: 4188_CR23
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0059639
  contributor:
    fullname: F Faião-Flores
– volume: 18
  start-page: 914
  issue: 10
  year: 2018
  ident: 4188_CR25
  publication-title: Curr Cancer Drug Targets
  doi: 10.2174/1568009618666180308105048
  contributor:
    fullname: RZ Morsi
– volume: 69
  start-page: 1633
  issue: 4
  year: 2022
  ident: 4188_CR17
  publication-title: Biotechnol Appl Biochem
  doi: 10.1002/bab.2233
  contributor:
    fullname: M Asadi
– volume: 11
  start-page: 461
  issue: 2
  year: 2020
  ident: 4188_CR8
  publication-title: Adv Nutr
  doi: 10.1093/advances/nmz110
  contributor:
    fullname: FH Nielsen
– volume: 135
  start-page: 111
  year: 2017
  ident: 4188_CR27
  publication-title: Biochimie
  doi: 10.1016/j.biochi.2017.02.001
  contributor:
    fullname: R Shakeri
– volume: 71
  year: 2022
  ident: 4188_CR11
  publication-title: J Trace Elem Med Biol
  doi: 10.1016/j.jtemb.2022.126958
  contributor:
    fullname: M Sevimli
– ident: 4188_CR16
  doi: 10.4238/gmr.15028300
– volume: 176
  start-page: 278
  issue: 2
  year: 2017
  ident: 4188_CR28
  publication-title: Biol Trace Elem Res
  doi: 10.1007/s12011-016-0824-y
  contributor:
    fullname: SE Kobylewski
– volume: 111
  start-page: 339
  year: 2014
  ident: 4188_CR36
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2014.157
  contributor:
    fullname: H Wang
– volume: 10
  start-page: 955
  issue: 4
  year: 2021
  ident: 4188_CR7
  publication-title: Cells
  doi: 10.3390/cells10040955
  contributor:
    fullname: F Galuppini
– volume: 8
  start-page: 23996
  issue: 14
  year: 2017
  ident: 4188_CR18
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.15098
  contributor:
    fullname: P Li
– volume: 73
  year: 2022
  ident: 4188_CR19
  publication-title: J Trace Elem Med Biol
  doi: 10.1016/j.jtemb.2022.127043
  contributor:
    fullname: E Kahraman
– volume: 186
  start-page: 226
  issue: 1
  year: 2018
  ident: 4188_CR22
  publication-title: Biol Trace Elem Res
  doi: 10.1007/s12011-018-1280-7
  contributor:
    fullname: H Khaliq
– volume: 70
  year: 2022
  ident: 4188_CR12
  publication-title: J Trace Elem Med Biol
  doi: 10.1016/j.jtemb.2022.126923
  contributor:
    fullname: E Cebeci
– volume: 134
  start-page: 1669
  issue: 8
  year: 2009
  ident: 4188_CR14
  publication-title: Analyst
  doi: 10.1039/b823234b
  contributor:
    fullname: AS Acerbo
– volume: 38
  start-page: 408
  year: 2014
  ident: 4188_CR35
  publication-title: Cancer Epidemiol
  doi: 10.1016/j.canep.2014.05.001
  contributor:
    fullname: L Yu
SSID ssj0017293
Score 2.421883
Snippet Medullary thyroid cancer (MTC) is a highly aggressive and chemotherapy-resistant cancer originating from the thyroid's parafollicular C cells. Due to its...
Medullary thyroid cancer (MTC) is a highly aggressive and chemotherapy-resistant cancer originating from the thyroid’s parafollicular C cells. Due to its...
SourceID proquest
crossref
pubmed
SourceType Aggregation Database
Index Database
Title In Vitro Effects of Boric Acid on Cell Cycle, Apoptosis, and miRNAs in Medullary Thyroid Cancer Cells
URI https://www.ncbi.nlm.nih.gov/pubmed/38689139
https://search.proquest.com/docview/3049719798
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Ja9tAFB6c5NJLaZsuThemUHpRBNZiLUdZkVND4kCjlOQkpJkRESQjo6Xg_vq-WSw1LYX0UDCSPXje4b2PN28fhD6VLvOsglhmYYfMdH1KzMILA7MEaxlOF7AomLzE9tJfXwcniZtMJrs6rnHtv0oa1kDWonP2H6Q9EIUF-A4yhydIHZ6PkvuKG9-qrqmNZKzUWIhBIEZEKipyA7EI18VbogqJo0296epWjRoQUfT76us6klWy53AMAUqarZHebpsadscCI42k0D5IB1eDDu2aHFQFU1Xphp4lNMScb4TxurDuqHo36iUxecH7hoxYvWQyh--rW9zPxY9FTPLbaqjTOalp36i48E3-vf8xYIepK_9O1Z47RUfEdYpC09dhDtv9JWPDtGqei3Yr2Tr3p-Kf6UZoFfKV2y1AhjMec7vU_voiW16dnWVpcp3uoQMbFBTox4NolZ4uh_wTuByObrFSjZa_031oxvzFN5E2SvoMPdXOBY4UKp6jCeMv0GHE866-3-LPWJb7yjzKIWIrjiVQsAYKrkssgYIFUHDNsRAzlkA5xgNMjjGABCuQ4IrjASRYgwQrkMjd7Ut0tUzS-Iup79wwiR0GnWl5ZUmJGFpol2BZEpuUNHcLp2Tg9_uel_vufOYSwux5bjGaE3Bhg5DCH10yo6RwXqF9XnP2BuHZjPrgLtg0CHK3LJyQEFLOHfEpbLDsp8jYsTDbqNEq2ThEWzA8A4ZnkuGZM0Ufd1zOQAOKtFbOWd23mUgU-1boh8EUvVbsH-g5gSfy8OHRI3a_RU9G4L1D-13Ts_dor6X9Bw2Pn8Iae6w
link.rule.ids 315,782,786,27933,27934
linkProvider Springer Nature
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=In+Vitro+Effects+of+Boric+Acid+on+Cell+Cycle%2C+Apoptosis%2C+and+miRNAs+in+Medullary+Thyroid+Cancer+Cells&rft.jtitle=Biological+trace+element+research&rft.au=Y%C4%B1ld%C4%B1r%C4%B1m%2C+Onurcan&rft.au=Se%C3%A7me%2C+M%C3%BCcahit&rft.au=Dodurga%2C+Yavuz&rft.au=Mete%2C+G%C3%BCl%C3%A7in+Abban&rft.date=2024-04-30&rft.eissn=1559-0720&rft_id=info:doi/10.1007%2Fs12011-024-04188-3&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0163-4984&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0163-4984&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0163-4984&client=summon